GlaxoSmithKline plc (NYSE:GSK) – Analysts at Svb Leerink issued their FY2019 EPS estimates for shares of GlaxoSmithKline in a research note issued to investors on Monday, December 2nd. Svb Leerink analyst G. Porges expects that the pharmaceutical company will earn $3.28 per share for the year. Svb Leerink has a “Outperform” rating on the stock. Svb Leerink also issued estimates for GlaxoSmithKline’s FY2020 earnings at $3.41 EPS, FY2021 earnings at $3.54 EPS, FY2022 earnings at $3.78 EPS and FY2023 earnings at $4.01 EPS.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, October 30th. The pharmaceutical company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.10. GlaxoSmithKline had a return on equity of 92.73% and a net margin of 13.76%. The company had revenue of $11.57 billion during the quarter, compared to the consensus estimate of $11.34 billion.
Shares of GlaxoSmithKline stock opened at $44.65 on Wednesday. The stock has a market capitalization of $113.44 billion, a P/E ratio of 14.13, a P/E/G ratio of 3.00 and a beta of 0.69. GlaxoSmithKline has a 52-week low of $36.41 and a 52-week high of $46.01. The company has a debt-to-equity ratio of 1.38, a quick ratio of 0.56 and a current ratio of 0.82. The stock’s 50-day simple moving average is $44.17 and its 200 day simple moving average is $41.66.
Several institutional investors and hedge funds have recently modified their holdings of the company. Berman Capital Advisors LLC lifted its position in GlaxoSmithKline by 58.1% during the second quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Prestige Wealth Management Group LLC purchased a new position in GlaxoSmithKline in the 2nd quarter worth approximately $26,000. Prime Capital Investment Advisors LLC bought a new position in shares of GlaxoSmithKline in the 3rd quarter worth $26,000. Financial Gravity Wealth Inc. raised its position in shares of GlaxoSmithKline by 62.7% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 308 shares in the last quarter. Finally, Ellis Investment Partners LLC raised its position in shares of GlaxoSmithKline by 144.5% during the 3rd quarter. Ellis Investment Partners LLC now owns 1,022 shares of the pharmaceutical company’s stock valued at $43,000 after buying an additional 604 shares in the last quarter. Hedge funds and other institutional investors own 11.27% of the company’s stock.
In other news, major shareholder Plc Glaxosmithkline bought 357,142 shares of the stock in a transaction on Friday, October 18th. The shares were acquired at an average cost of $28.00 per share, for a total transaction of $9,999,976.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 10.00% of the company’s stock.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: What are Institutional Investors?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.